FARALLON CAPITAL MANAGEMENT, L.L.C.FARALLON CAPITAL MANAGEMENT, L.L.C.

Institutional investor · Portfolio as of Q2 2024

Top Holdings167 positions

Checking export access…
Activity:
SPYSPY
PUT

State Street Spdr S&p 500 Etf Trust TR UNIT

8.9M$4.8B20.8%———
Decreased
—

HESS CORP

6.8M$1B4.3%——
3 qtrssince 2023-Q4
Increased
62
IWMIWM
PUT

iShares Trust RUSSELL 2000 ETF

4.3M$862.3M3.7%———
New
—

UnitedHealth Group Inc.

1.6M$824.1M3.5%$451.86+7.07%
6 qtrssince 2023-Q1
Decreased
0

SALESFORCE COM INC

2.9M$757.6M3.3%$201.91+25.97%
19 qtrssince 2019-Q4
Increased
81

IQVIA Holdings Inc.

2.9M$618M2.7%$165.53+27.74%
23 qtrssince 2018-Q4
Increased
56

EXELIXIS INC

27.1M$609M2.6%$19.15+17.33%
23 qtrssince 2018-Q4
Increased
55

ARAMARK

16.9M$575.9M2.5%$25.80+29.00%
15 qtrssince 2020-Q4
Decreased
0

AON PLC

1.9M$550.5M2.4%$303.01-4.32%
2 qtrssince 2024-Q1
Increased
87

Microsoft Corp.

1.2M$537.6M2.3%$213.45+105.77%
23 qtrssince 2018-Q4
Decreased
0

NEW YORK TIMES CO

9.9M$508M2.2%$41.34+21.40%
17 qtrssince 2020-Q2
Decreased
0

NATERA INC

4.5M$483M2.1%$65.70+64.81%
13 qtrssince 2021-Q2
Increased
61
IBBIBB
PUT

iShares Trust ISHARES BIOTECHNOLOGY ETF

3.5M$480.4M2.1%———
Unchanged
—

NASDAQ INC

7.5M$452.4M1.9%$57.63+2.63%
4 qtrssince 2023-Q3
Decreased
0

TRANSUNION

6M$447.6M1.9%$86.03-14.44%
23 qtrssince 2018-Q4
Decreased
0
CTLTCTLTDelisted

CATALENT INC

7.6M$427.3M1.8%——
3 qtrssince 2023-Q4
Increased
79

INTUIT

629,097$413.4M1.8%$422.31+53.85%
7 qtrssince 2022-Q4
Increased
57

Thermo Fisher Scientific Inc

739,156$408.8M1.8%$431.27+27.25%
19 qtrssince 2019-Q4
Decreased
0

REVOLUTION MEDICINES INC COM

9.8M$378.7M1.6%$31.41+23.56%
14 qtrssince 2021-Q1
Increased
62

SAREPTA THERAPEUTICS INC

2.3M$362.6M1.6%$115.75+36.50%
12 qtrssince 2021-Q3
Decreased
0
$23.3B
AUM
167
Positions
Q2 2024
Filing
HI score · 1.5/5
Quarterly 13F Value Change
+7%Q1'23$16.5B+1%Q2'23$16.7B+6%Q3'23$17.7B-10%Q4'23$16B+6%Q1'24$17B-0%Q2'24$16.9B
Activity profile
$ moved · Q2'24
New24%Increased24%Decreased30%Exited21%
Composition
Equity vs derivatives
Equity73%Puts27%Calls0%
Holding period
Avg 2.2 years
<1Q10%1-4Q29%1-2Y10%2Y+51%

FARALLON CAPITAL MANAGEMENT, L.L.C. manages $23.3B across 167 positions as of Q2 2024. Top holdings: SPY puts (20.8%), HES (4.3%), IWM puts (3.7%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1.5/5.0.

Q2 2024 Summary

Active quarter - 20 new positions, 30 exits, 32 increased. Top move: AON (INCREASED, conviction 87). Portfolio: $23.3B across 167 positions.

Top holdings by portfolio weight

Total AUM$17B
HES4.29%
UNH3.54%
CRM3.25%
IQV2.65%
EXEL2.61%
ARMK2.47%
AON2.36%
MSFT2.31%
NYT2.18%
NTRA2.07%
Other1.94%

Portfolio allocation by GICS sector

Sectors11
Healthcare36.91%
Technology15.82%
Unknown13.68%
Financial Services13.37%
Communication Services7.19%
Industrials6.75%
Real Estate2.43%
Consumer Cyclical1.78%
Basic Materials1.22%
Consumer Defensive0.78%
Other0.07%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Technology, Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Below Average(1.5 / 5.0)
Holdings P&L47
Conviction44
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
BBIOBBIOBRIDGEBIO PHARMA INC
Q4 2024 → Q2 2026+9M shares+$755.7M
7Q
CRNXCRNXCRINETICS PHARMACEUTICALS IN
Q4 2024 → Q2 2026+7.8M shares+$277M
5Q
BSXBSXBOSTON SCIENTIFIC CORP
Q2 2025 → Q2 2026+6.8M shares+$69.5M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used